Product Description
Meropenem pure USP injection 96036-03-2
AI Product Description
*The following content is generated by AI and is for reference only.
Meropenem pure USP injection is a broad-spectrum, bactericidal antibiotic belonging to the carbapenem class of beta-lactam agents. Synthesized to meet United States Pharmacopeia (USP) standards for purity and potency, this sterile solution is primarily indicated for the treatment of serious bacterial infections caused by susceptible organisms. Its molecular formula is C₁₇H₂₅N₃O₅S, with a corresponding CAS Registry Number of 119478-22-9. The drug functions by inhibiting bacterial cell wall synthesis through high-affinity binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Notably, Meropenem exhibits exceptional stability against most beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), which often confer resistance to other antibiotics like cephalosporins.
This formulation is widely utilized in hospital settings for treating complicated intra-abdominal infections, community-acquired pneumonia, meningitis, febrile neutropenia, and complicated urinary tract infections. It is particularly effective against Gram-negative bacteria such as *Pseudomonas aeruginosa*, *Escherichia coli*, and *Klebsiella* species, as well as various Gram-positive cocci and anaerobes. Unlike some other carbapenems, Meropenem can be administered via intravenous infusion over fifteen minutes, making it suitable for rapid therapeutic intervention in critical care scenarios. The "pure USP" designation ensures that the active pharmaceutical ingredient meets rigorous quality control benchmarks regarding identity, strength, quality, and purity, guaranteeing patient safety and consistent clinical outcomes.
Common side effects may include nausea, vomiting, diarrhea, headache, and rash, while rare but severe adverse reactions can involve seizures, particularly in patients with central nervous system disorders or renal impairment requiring dose adjustment. Due to its potent spectrum and stability profile, Meropenem remains a cornerstone therapy for empiric treatment of severe sepsis and multidrug-resistant infections. However, prudent prescribing practices are essential to mitigate the risk of developing further antimicrobial resistance. Continuous monitoring of renal function is recommended during prolonged therapy to ensure optimal dosing and minimize toxicity risks associated with accumulation.